Log in
Enquire now
‌

US Patent 10137120 Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Patent 10137120 was granted and assigned to ChemoCentryx on November, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
ChemoCentryx
ChemoCentryx
0
Current Assignee
ChemoCentryx
ChemoCentryx
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
101371200
Patent Inventor Names
Jay P. Powers0
Rebecca M. Lui0
Xi Chen0
Yibin Zeng0
Antoni Krasinski0
Jeffrey P. McMahon0
Junfa Fan0
Lianfa Li0
...
Date of Patent
November 27, 2018
0
Patent Application Number
145416370
Date Filed
November 14, 2014
0
Patent Citations Received
‌
US Patent 11883391 Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
0
Patent Primary Examiner
‌
Jeffrey S Lundgren
0
Patent abstract

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10137120 Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.